A 28-year-old female presents with bilateral optic neuritis and transverse myelitis extending over 3 vertebral segments. MRI spine shows a long central cord lesion at C3-C6. Serum AQP4-IgG is positive. How does NMOSD differ from MS clinically, on MRI, and in CSF analysis? Does she need disease-modifying therapy, and which agents are now approved specifically for NMOSD (eculizumab, inebilizumab, satralizumab)?
For peer discussion only — not a substitute for clinical judgment. Verify with authoritative sources.
0
0 answers0 Answers
💬
No answers yet
Be the first to share your clinical insight.
Your Answer
Be specific. Your credentials will be shown with your answer.
References (strongly recommended)
Answers with guideline links, journal citations, or textbook references are more trusted by the community.